logo
Plus   Neg
Share
Email

Bristol-Myers Squibb Reports Phase 3 CheckMate -227 Trial Results - Quick Facts

Bristol-Myers Squibb Company (BMY) said Part 1a of the Phase 3 CheckMate -227 trial evaluating Opdivo plus low-dose Yervoy met the co-primary endpoint of overall survival, demonstrating a superior benefit versus chemotherapy in first-line non-small cell lung cancer patients whose tumors express PD-L1 =1%. In an exploratory analysis of patients in Part 1b whose tumors do not express PD-L1, a survival benefit was also observed with Opdivo plus low-dose Yervoy.

However, part 2 of the CheckMate -227 trial, evaluating Opdivo plus chemotherapy, did not meet the pre-specified primary endpoint of overall survival versus chemotherapy in patients with non-squamous histology, regardless of PD-L1 status.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Global PC shipments returned to growth in the second quarter of 2020 after seeing a significant decline in the preceding first quarter due to COVID-19 related supply-chain disruptions, according to reports by two research firms. The PC market returned to growth in the quarter as production ramped up and vendors restocked their supplies to near-normal levels. The bankruptcy filing of America's oldest apparel retailer Brooks Brothers has ignited significant interest from potential buyers for the brand. WHP Global and a venture backed by Authentic Brands Group LLC and Simon Property Group, Inc., are reportedly considering bids for the retailer. WHP Global owns the ANNE KLEIN and JOSEPH ABBOUD brands. Sundial Herbal Products has recalled around 65 products, which were misbranded and currently unapproved drugs, the U.S. Food and Drug Administration said in a statement. The recall follows an order by a federal judge in June to stop distributing the company's unapproved new drugs. The affected items include herbal products and dietary supplements.
Follow RTT